
Supplementary information

A brain reward circuit inhibited by next-generation weight-loss drugs in mice

In the format provided by the
authors and unedited

A Brain Reward Circuit Inhibited By Next-Generation Weight Loss Drugs in Mice

Authors

Elizabeth N. Godschall^{1†}, Taha Bugra Gungul^{1†}, Isabelle R. Sajonia^{1†}, Aleya K. Buyukaksakal¹, Orien Dong-Ang Li¹, Sophia Ogilvie¹, Austin B. Keeler¹, Guilian Tian², Yu Shi¹, Omar Koita^{3,4}, Xinzhu Guo¹, Tyler C. J. Deutsch^{5,6}, Eric J. Steacy^{5,7}, Maisie Crook¹, YuChen Zhang⁷, Nicholas J. Conley^{1,7}, Gulsun Memi^{1,8}, Addison N. Webster^{1,7}, O. Yipkin Calhan¹, Weile Liu¹, Amani Akkoub¹, Karan Malik¹, Kaleigh I. West¹, Sara Michel-Le¹, Arun Karthikeyan¹, Grace van Gerven¹, Olivia A. Dell'Aglio¹, Kevin T. Beier², Larry S. Zweifel^{3,4}, Manoj K. Patel^{5,7}, John N. Campbell^{1,7,9}, Christopher D. Deppmann^{1,7, 9-11*}, Ali D. Güler^{1,7,9*}

¹Department of Biology, University of Virginia; Charlottesville, VA 22904, USA.

²Department of Physiology and Biophysics, University of California, Irvine; Irvine, CA, 92617, USA

³Department of Pharmacology, University of Washington; Seattle, WA, 98195, USA

⁴Department of Psychiatry, University of Washington; Seattle, WA, 98195, USA

⁵Department of Anesthesiology, University of Virginia; Charlottesville, VA 22904, USA.

⁶Edward Via College of Osteopathic Medicine; Blacksburg, VA, 24060, USA

⁷Neuroscience Graduate Program, University of Virginia; Charlottesville, VA 22903, USA.

⁸Department of Physiology, School of Medicine, Adiyaman University; Adiyaman 02040, Turkey.


⁹Program in Fundamental Neuroscience, University of Virginia; Charlottesville, VA 22904, USA.

¹⁰Department of Cell Biology, University of Virginia; Charlottesville, VA 22904, USA.


¹¹Department of Biomedical Engineering, University of Virginia; Charlottesville, VA 22904, USA.

*Corresponding author. Email: deppmann@virginia.edu and aguler@virginia.edu.


†These authors contributed equally to this work.




Supplemental Data Fig. 1. Home cage monitoring heatmaps of *Glp1r^{S33W}* mice. (a), Representative image of home cage set-up (dimensions: 30 x 30 x 43.5 cm) with bedding, showing calibrated positions of wheel, IR translucent shelter (10.5 x 10.5 x 6 cm), food hopper (5.5 cm from floor), and water bottle spout (5 cm from floor) identified in white outline (top). Videos were recorded using a top-down greyscale video recording system. (b) 9 Keypoints tracked on mice using SLEAP: nose, ears (L/R), tail base, and five body center points. (c), Coordinate-based heatmaps of nose keypoint trajectories recorded at 25 fps over 2-hour sessions for each treatment (ZT 12-14). Color scale represents dwelling time in minutes.




Supplemental Data Fig. 2. Machine-learning assisted behavioral analysis pipeline. Blue squares represent video pre-processing steps. Social LEAP Estimates Animal Poses (SLEAP) was used to extract nine keypoint coordinates for each mouse in the videos (**Fig. 2b-c**, **Supplemental Data Fig. 1b-c**). Keypoint Motion Sequencing (Keypoint-MoSeq) identified behavioral syllables from these coordinates (**Fig. 2d-f**, **Extended Data Figures 3-4**, **Supplemental Data Figures 3-4**). Pink squares represent Python scripts and the yellow square represents R scripts used for the analysis of Keypoint-MoSeq results: syllable-level analysis (**Fig. 2d-f**, **Extended Data Figures 3-4**, **Supplemental Data Fig. 4**), locations (identify regions of interest), location_behavior (**Fig. 2g-y**), build_dataset, Visualization (**Fig. 2g**, **2s-x**), and PCA (**Fig. 2y**, **Extended Data Fig. 6y-z**).




Supplemental Data Fig. 3. Keypoint-MoSeq trajectory plots of behavioral syllables. Syllables identified from keypoint coordinates by Keypoint-MoSeq were sorted into 11 categories by trained raters using grid movies generated for each syllable. The proportion of each syllable category is presented as a percentage. Rare syllables (minimum frequency < 0.5% but $\geq 0.01\%$) are not visually depicted but were included in the analysis.




Supplemental Data Figure 4. Behavioral syllable usage and velocity. **a–c**, Each row represents an individual mouse assigned to one of five test conditions: liraglutide (Lira), danuglipron (Dan), orforglipron (Orfo), lithium chloride (LiCl), or pre-fed/satiated (Fed). **b**, Distribution of velocity usage over the two-hour home cage recording period. **c**, Percent usage of behavioral syllables identified by Keypoint-MoSeq. **d–g**, Change in usage of syllables across drug conditions relative to paired vehicle control. The top 10% of changes from baseline across all drug groups are labeled with their syllable identity number. Syllables above the dashed line show increased usage under drug conditions; those below show decreased usage for **(d)** LiCl, **(e)** Dan, **(f)** Lira, and **(g)** Orfo.




Supplemental Data Fig. 5. Validation of AAV-hSyn-DIO-hGLP1R virus. **a**, Validation of human GLP1R (hGLP1R; red) expression in the CeA of Glp1r-Cre mice injected with AAV-DIO-hGLP1R (right). hGLP1R protein expression is absent in Glp1r-Cre mice injected with AAV-DIO-mGlp1r in the CeA (left). Scale bar = 200 μ m. **b**, Quantification of hGLP1R+ cells and average number of Glp1r+ cells (measured in Glp1r-Cre;tdTomato mice) in the CeA, DMH, or NTS/AP per section. Sample sizes per section: CeA hGLP1R $n = 23$, tdTomato $n = 3$; DMH hGLP1R $n = 18$, tdTomato $n = 3$; NTS/AP hGLP1R $n = 15$, tdTomato $n = 6$. **c-j**, Fluorescent microscopy images of the brain regions stereotactically injected with AAV-DIO-hGLP1R. Images from Allen Brain Atlas, with regions of interest in bold and hGLP1R antibody staining (green) in the (**c,d**) basomedial hypothalamus (BMH), (**e,f**) DMH, (**g,h**) NTS/AP, or (**i,j**) CeA. Scale bars = 200 μ m. Data are presented as mean $\pm$ SEM.




Supplemental Data Fig. 6. Transcriptomic profiling of CeA^{Glp1r} neurons. a-b, Coexpression analysis of Glp1r mRNA and glutamatergic markers (Slc17a7 and Slc17a6) and Glp1r and GABAergic markers (Gad1, Slc6a1, and Slc32a1). **c,** Dotplot showing Glp1r is expressed in the Vdr cluster that contains GABAergic markers. The transcriptomic analyses confirm that CeA^{Glp1r} neurons are GABAergic³⁹.



Supplemental Data Fig. 7. CeA *Glp1r* and *Pnoc* spatial expression analysis. (a-l) Representative MERFISH images from the Allen Brain Atlas of 12 marker transcripts in the CeA, showing relative expression levels from low (yellow) to high (purple)⁴⁰. **m**, Dotplot showing *Glp1r* and *Pnoc* are expressed in the Vdr cluster³⁹. **n**, Representative image for *Pnoc* RNAscope staining (green) and tdTomato protein expression (magenta) demonstrating some but not total overlap (white) between cell types in the CeA of *Glp1r*-Cre;TdTomato mice (29.9% overlap $\pm$ 3.8, $n = 3$ mice).



Supplemental Data Fig. 8. Validation of CeA^{Glp1r} targeting and VTA innervation. **a**, Representative images of AAV-DIO-ChR2-eYFP expression targeted to the CeA of Glp1r-Cre mice (green; $n = 6$). **b**, Tyrosine hydroxylase (Th) expression in the VTA (magenta). **c**, Axon fiber projections from CeA^{Glp1r} neurons into the VTA, and **d**, colocalization of Th with CeA^{Glp1r} fibers in the VTA. **e**, Traces of superimposed AAV-DIO-ChR2-eYFP injection targeting per mouse, collapsed on the Allen Brain Atlas figure.



Supplemental Data Figure 9. *Glp1r^{flox/flox}* AAV-Cre or AAV-GFP food intake. a-b, Validation of AAV-GFP (a) or AAV-Cre (b) targeting the CeA of *Glp1r^{flox/flox}* mice. c-d, SD (c) and HFD (d) chow consumption 4 hours after injection of vehicle (Veh) or liraglutide (Lira) in AAV-GFP expressing mice. ($n = 11$, Paired t-test, *** $P < 0.001$). e-f, SD (e) and HFD (f) chow consumption 4 hours after injection of Veh or Lira in AAV-Cre expressing mice. ($n = 12$, Paired t-test, *** $P < 0.001$). Data are represented as means $\pm$ SEM.